Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge MD, Cook GJR, Chua S, Du Y, Hafeez S, Murray I, Padhani AR, Staffurth J, Tree A, Stidwill H, Finch J, Curcean A, Chatfield P, Perry S, Koh DM, Hall E. Parker C, et al. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad077. doi: 10.1093/jncics/pkad077. JNCI Cancer Spectr. 2023. PMID: 37788117 Free PMC article. Clinical Trial.
Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy.
Jackson AS, Parker CC, Norman AR, Padhani AR, Huddart RA, Horwich A, Husband JE, Dearnaley DP. Jackson AS, et al. Among authors: parker cc. Clin Oncol (R Coll Radiol). 2005 May;17(3):167-71. doi: 10.1016/j.clon.2004.08.007. Clin Oncol (R Coll Radiol). 2005. PMID: 15901000
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E. Dearnaley D, et al. Among authors: parker c. Lancet Oncol. 2012 Jan;13(1):43-54. doi: 10.1016/S1470-2045(11)70293-5. Epub 2011 Dec 12. Lancet Oncol. 2012. PMID: 22169269 Free article. Clinical Trial.
Radium-223 for the treatment of prostate cancer.
Hafeez S, Parker C. Hafeez S, et al. Among authors: parker c. Expert Opin Investig Drugs. 2013 Mar;22(3):379-87. doi: 10.1517/13543784.2013.761974. Epub 2013 Jan 15. Expert Opin Investig Drugs. 2013. PMID: 23316941 Review.
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Omlin A, et al. Among authors: parker c. Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8. Br J Cancer. 2013. PMID: 23928659 Free PMC article.
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G. Lorente D, et al. Among authors: parker c. Br J Cancer. 2014 Dec 9;111(12):2248-53. doi: 10.1038/bjc.2014.531. Epub 2014 Oct 14. Br J Cancer. 2014. PMID: 25314055 Free PMC article.
3,098 results